MedPath

A study on comparison between monetary & clinical benefit gained by stopping antibiotic therapy early in high risk type of fever with blood neutrophil count less than 500 per micro litre in children with cancer

Phase 3
Conditions
Health Condition 1: D701- Agranulocytosis secondary to cancer chemotherapy
Registration Number
CTRI/2020/07/026858
Lead Sponsor
AIIMS
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Age 2-18 yrs

2. De novo and relapsed AML & ALL undergoing induction & reinduction with febrile neutropenia

Exclusion Criteria

1. Already enrolled once in previous episode

2. Retrovirus positive patients

3. Patients who require >= 3rd line antibiotics during febrile neutropenia episode prior to becoming afebrile

4. Patients who require therapeutic antifungals during febrile neutropenia episode prior to enrolment

5. Patients who require ionotropic support / mechanical ventilation during treatment course for febrile neutropenia episode prior to enrolment

6. Severe renal function impairment (defined as a creatinine clearance below 30 ml/min) during treatment course for febrile neutropenia prior to enrolment

7. The clinical or microbiological or radiologic focus of infection during treatment course for febrile neutropenia prior to enrolment

8. Patient undergone stem cell transplant

9. Denying consent

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath